All Posts By

JAG Shaw Baker

How To Be Patient Centric In The Age Of GDPR

By | GDPR, Guest Posts

The General Data Protection Regulation (GDPR) comes into force on 25 May 2018. It’s imperative that anyone working with or for patients, particularly in digital healthcare, understands what it means to them and their products and services.  The current focus of many GDPR-readiness seminars and guidelines is largely on the internal – for example, scoping the role of the Data Protection Officer; defining data controllers versus data processors, and unpicking the various justifications for legal processing of data. All crucial stuff, of course. But through focussing on these internal aspects of implementing GDPR, there’s a danger of missing something crucial….

Read More

This Week In Investor News

By | Client news, Current Affairs, Entrepreneurs, Investor and VC News, investors

In investor news, our client ETF Partners recently led a £70 million deal for E-Leather, a UK environmentally friendly materials technology company using traditional leather fibres and high-powered water to produce a technologically advanced eco-leather material. “JAG Shaw Baker has been great at giving guidance through this complicated transaction. The process would not have been as smooth without their help,” said Arne Morteani, Partner, ETF Partners. Considered an advanced GreenTech company, E-Leather creates the look and feel of traditional leather with the performance and consistency of an engineered product through a sustainable process. In 2017, E-Leather and Nike announced a strategic…

Read More

Funding AI, VR And AR Startups In Medtech For Growth

By | Biotech, Current Affairs, James Shaw, Knowledge, Life Sciences, Partner Insight

Our partner and co-founder, James Shaw, recently participated in a panel discussion about funding artificial intelligence (AI), virtual reality (VR) and augmented reality (AR) start-ups in healthcare at Biotech and Money/Medtech and Money World Congress on 5 February 2018. Panellists included Isabel van de Keere, CEO at Immersive Rehab, Tommi Lehtonen, CEO at Blueprint Genetics, and Andrew Chapman, Digital Health, Sector Lead at Digital Catapult. As part of that panel, James wrote an opinion piece for Biotech and Money called The New Cambrian Era for Biotech Startups. Here is the article in full. ________________________________________________________________________ Healthcare is the hottest new sector for start-ups…

Read More

Life Sciences Round Up

By | Biotech, Client news, investors, Life Sciences, Series A, Startups

We’ve seen several months of milestones from our Life Sciences clients – from funding rounds to industry recognition. Here’s short round-up of their successes. INVESTMENT Our client Julz, a healthcare investment company, was one of the investors in SurgaColl in their Series A. SurgaColl is a regenerative medicine company focussed on tissue repair. The funding allowed the company to establish a new commercial headquarters in Alderley Park, Cheshire which is one of the largest bioscience campuses in the UK with more than one million square feet of prime lab space. Julz, also closed a Series A round for Stent Tek…

Read More

GDPR And The Implications Of Biometric Data

By | Biometric Data, Data & Privacy, Knowledge

Our associate, Ashley Williams worked with our client Aimbrain to co-author a whitepaper, GDPR & Beyond: Collaboration, Consent, Capture and Care in the World of Biometric Data. Aimbrain has a multi-module biometrics platform that allows institutions to authenticate their customer’s identity on any device across any channel. The whitepaper looks at the first corporate use cases in the 1960s and notes that biometrics have become commonplace across banking, government, enterprise applications, physical access and more. Today, using fingerprint and facial scans to unlock devices has put biometrics in the mainstream, and the industry is worth an estimated value of $25.3 billion by…

Read More

Our New Cambridge Office

By | Brand, Current Affairs, Entrepreneurs, Knowledge, Life Sciences

We are very pleased to announce our new office in Cambridge. The office is part of our ongoing commitment to the Life Sciences ecosystem in the area and throughout the UK. The Life Sciences industry is worth around £64 Billion to the UK economy. The UK government is centering part of its new life sciences strategy to make Britain a world leader in Life Sciences on Cambridge. The Cambridge Cluster is already recognised as the hub of the UK life sciences industry with more than 400 companies employing an excess of 13,000 people. Earlier this year, Sir John Bell, Life…

Read More

Five Tips To Prepare Your Life Sciences Organisation For The GDPR

By | Current Affairs, Data & Privacy, GDPR, Intellectual Property

A recent survey from Clearswift asked companies if they felt they had all the necessary processes in place to be compliant for the pending General Data Protection Regulation (GDPR). The top five sectors from that survey that indicated they were ready included technology and telecommunications (32%), education (31%), IT (29%), business services (29%) and finance (29%). But the survey also revealed that healthcare was the least likely to be ready for GDPR and have the processes in place to comply with the legislation. GDPR takes effect on 25 May 2018 and introduces substantial changes to the EU data protection regime. The GDPR…

Read More

In Client News: Crane Venture Partners Leads $30 M Series C For AI Startup

By | Artificial Intelligence, Client news, Entrepreneurs, Investor and VC News, investors, Series C

Congratulations to our client, Crane Venture Partners on leading the Series C $30 Million funding round for London-based Onfido. Onfido uses artificial intelligence algorithms to help websites verify people’s identities by merely using a photo-based identity document and a selfie to curb hackers and security breaches that have exposed personal information of millions of people globally. This is the second round of investment for Onfido following their round of $30 Million including two of our clients Idinvest and Wellington. In an interview with TechCrunch, Scott Sage, co-founder and partner, Crane Venture Partners, said that Onfido is one of the leading data enterprise…

Read More

Bossa Raises $10 Million Series A For Its Simulation Game

By | Client news, Current Affairs, Entrepreneurs, Gaming, Investor and VC News

Summer turns to fall, and our clients continue to show no signs of stopping. In gaming news, we advised London-based Bossa Studios on its $10 Million Series A fundraise ahead of the launch of its upcoming simulation game Worlds Adrift. Atomico led the investment with participation from existing investor, London Venture Partners. Atomico co-founder and partner Mattias Ljungman and executive-in-residence Alexis Bonte, will both join Bossa’s board of directors. In an ongoing validation of the strength of UK and European tech, Bossa will be making use of Improbable’s ground-breaking SpatialOS platform in the creation of Worlds Adrift. The Cambridge-born tech firm has…

Read More

Habito Raises £18.5 Million In A Series B Round Led By Atomico

By | Client news, Current Affairs, Entrepreneurs, Investor and VC News, investors, Startups

JAG Shaw Baker is proud to have advised our client Habito, on their £18.5 Million Series B round led by Atomico. The raise supports Habito, one of the standout ‘PropTech’ companies in the UK, and their vision to leverage the large inefficiencies inherent in the mortgage market. The round brings the total raised by the company to a total of £27m and the funding will be used for marketing and other product development as well as the company’s plans to expand its offering to other parts of the mortgage process such as home and life insurance. Daniel Hegarty, CEO, Habito started the company in 2015. The JAG Shaw Baker team…

Read More

A cookie is a small file of letters and numbers that we store on your browser or computer, phone or tablet hard drive if you agree. more information

INFORMATION ABOUT OUR USE OF COOKIES Our website uses cookies to distinguish you from other users of our website. This helps us to provide you with a good experience and also allows us to improve our website. By continuing to browse the website, you are agreeing to our use of cookies. A cookie is a small file of letters and numbers that we store on your browser or computer, phone or tablet hard drive if you agree. We use the following cookies: • Strictly necessary cookies. These are cookies that are required for the operation of our website. They include, for example, cookies that enable you to return to a previous page. • Analytical/performance cookies. They allow us to recognise and count the number of visitors and to see how visitors move around our website when they are using it. This helps us to improve the way our website works, for example, by ensuring that users are finding what they are looking for easily. The analytical/performance cookies are provided on our behalf by Google Inc. to aid with reporting of user behaviour, market research and improving website functionality. This user behaviour is analysed in order to improve this website. To see how this applies to Google Analytics, visit You can stop tracking by Google Analytics by visiting COOKIE DURATION The strictly necessary session cookies are a temporary cookie which remains in the cookie file of your browser until you close the browser. The other cookies will remain in the cookie file of your browser after the closing of the browser, and will become active again when you reopen this website. The different cookies have different expiration dates. Following expiry of a cookie, a new version of that cookie will be downloaded when you next visit this website, unless you have withdrawn your consent in the meantime. You can block cookies by activating the setting on your browser that allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or parts of our website. Contact If you have any queries regarding this cookie policy please contact us at